<p>n = 13. Circle size corresponds to weighting by patient numbers of each cohort. R2 is the proportion of variability in the data that is accounted for by the weighted univariate regression model.</p
<p>ARR = Annualized relapse rate over 2 years, Logistic regression: Outcome was coded as 1 for at ...
<div><p>Background</p><p>Relapsing-remitting dynamics are a hallmark of autoimmune diseases such as ...
Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of...
<p>N = 13. Circle size corresponds to weighting by patient numbers of each cohort. R2 is the proport...
BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...
<div><h3>Background</h3><p>Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomiz...
<p>Coefficient estimates and coefficient of determination (adjusted R2) of univariate regression mod...
<p>Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis r...
Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...
Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...
BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...
*<p> <i>15996 pts; p-value for trend 0.032; <sup>Λ</sup>14543 pts; °11998 pts; § p<...
<p>The combinations of biomarkers were down or up-regulated simultaneously in the individuals. The r...
<p>RRMS = Relapsing-remitting Multiple Sclerosis, Pub.Year = Year of Publication, N = patients in pl...
Background: In multiple sclerosis (MS) studies, the most appropriate model for the distribution of t...
<p>ARR = Annualized relapse rate over 2 years, Logistic regression: Outcome was coded as 1 for at ...
<div><p>Background</p><p>Relapsing-remitting dynamics are a hallmark of autoimmune diseases such as ...
Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of...
<p>N = 13. Circle size corresponds to weighting by patient numbers of each cohort. R2 is the proport...
BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...
<div><h3>Background</h3><p>Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomiz...
<p>Coefficient estimates and coefficient of determination (adjusted R2) of univariate regression mod...
<p>Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis r...
Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...
Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RM...
BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...
*<p> <i>15996 pts; p-value for trend 0.032; <sup>Λ</sup>14543 pts; °11998 pts; § p<...
<p>The combinations of biomarkers were down or up-regulated simultaneously in the individuals. The r...
<p>RRMS = Relapsing-remitting Multiple Sclerosis, Pub.Year = Year of Publication, N = patients in pl...
Background: In multiple sclerosis (MS) studies, the most appropriate model for the distribution of t...
<p>ARR = Annualized relapse rate over 2 years, Logistic regression: Outcome was coded as 1 for at ...
<div><p>Background</p><p>Relapsing-remitting dynamics are a hallmark of autoimmune diseases such as ...
Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of...